Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

NASDAQ:GNLX

Genelux Corporation

Last Close

2.18

25/09 14:39

Market Cap

85.54M

Beta: -

Volume Today

133.93K

Avg: 126.14K

PE Ratio

−7.81

PFCF: −14.62

People Not Available